Merck (NYSE: MRK) recently released its Q4 results, with revenues and earnings exceeding the street estimates.

Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...

Q4 2024 Earnings Call Transcript February 4, 2025 Merck & Co., Inc. misses on earnings expectations. Reported EPS is $1.72 ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...

Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable ...

Earnings season is in full swing in the pharma sector with major players sharing their latest results. On Tuesday (February 4 ...

Executives pulled back on a 2030 sales target of $11 billion as demand for the HPV shot shrinks amid China market turmoil.

Faced with the encroaching threats of patent expirations and generics, biopharma companies in 2024 invested 33% more in ...

The stock markets in the US opened higher on February 4 as investors remained cautious about China’s stance on the Trump ...

Morgan Stanley analyst Terence Flynn lowered the firm’s price target on Merck (MRK) to $106 from $113 and keeps an Equal Weight rating on the ...

AMD is shipping more desktop chips to keep up with the demand as the Ryzen 9800X3D remains hard to find in stock.

Merck on Tuesday missed earnings estimates, lowered its guidance for this year’s earnings, and withdrew a target for sales of ...